Agios Pharmaceuticals Inc

NASDAQ:AGIO   3:59:58 PM EDT
55.68
+0.46 (+0.83%)
Divestitures / Spin-offs, Share Repurchases, Earnings Announcements

Agios Pharmaceuticals To Sell Oncology Business To Servier For Up To $2 Billion Plus Royalties

Published: 12/21/2020 12:17 GMT
Agios Pharmaceuticals Inc (AGIO) - :agios Pharmaceuticals - to Focus on Developing and Commercializing Treatments for Genetically Defined Diseases.
Agios Pharmaceuticals - to Sell Oncology Business to Servier for Up to $2 Billion Plus Royalties.
Agios Pharmaceuticals - Deal Includes Receipt of $1.8 Billion in Upfront Cash, Potential $200 Million Regulatory Milestone Payment & Future Royalties.
Agios Pharmaceuticals - Deal Includes Transfer of Co's Oncology Portfolio, Including Marketed Medicine Tibsovo.
Agios Pharmaceuticals - Servier Will Also Acquire Co's Co-commercialization Responsibilities for Bristol Myers Squibb’s Idhifa.
Agios Pharmaceuticals - Deal Includes Co's Oncology Pipeline and Clinical Programs, Including Vorasidenib.
Agios Pharmaceuticals - Plans to Return at Least $1.2 Billion to Shareholders Following Deal Close.
Revenue is expected to be $2.75 Million
Adjusted EPS is expected to be -$1.32

Next Quarter Revenue Guidance is expected to be $3.19 Million
Next Quarter EPS Guidance is expected to be -$1.49

More details on our Analysts Page.